Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.
The properties of oral, direct inhibitors of factor Xa (e.g. rivaroxaban) and thrombin (e.g. dabigatran) have been examined the haemostasis and thromboembolism management. Preclinical studies have provided evidences for the effects of direct factor Xa or thrombin inhibition beyond anticoagulation, including anti-inflammatory and protective activities in atherosclerotic plaque development . Therefore, this study evaluates the protective effects of NAOC with the reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function by Endo-PAT2000 and intima-media thickness (IMT) of the carotid artery, which is used as a surrogate endpoint of atherosclerosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
Kyung Hee University
Seoul, South Korea
The changes in reactive hyperemia index (RHI)
Time frame: 12months
right and left maximum IMT of the common carotid artery (CCA)
Time frame: 24months
right and left mean IMT of the common carotid artery (CCA)
Time frame: 24months
adverse events
Time frame: 24months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.